Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vishal Gupta, Ranya Baabbad, Eva Hammerby, Annie Nikolajsen & Asrul Akmal Shafie. (2015) An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. Journal of Medical Economics 18:4, pages 263-272.
Read now
Read now
Vasil Valov, James Palmer, Marcin Czech, Alexandra Savova & Guenka Petrova. (2012) Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. Biotechnology & Biotechnological Equipment 26:2, pages 2937-2944.
Read now
Read now
Articles from other publishers (13)
Xingfang Qu, Zichao Wang, Yao Cheng, Qingwei Xue, Zimu Li, Lu Li, Liping Feng, Gesa Hartwigsen & Luyao Chen. (2022) Neuromodulatory effects of transcranial magnetic stimulation on language performance in healthy participants: Systematic review and meta-analysis. Frontiers in Human Neuroscience 16.
Crossref
Crossref
H. Iraqi, H. Jamoussi Kamoun & A. Boudiba. (2019) Initiation de l’insulinothérapie avec un analogue d’une insuline prémix chez le diabétique de type 2 : rationnel et consensus. Médecine des Maladies Métaboliques 13, pages eS8-eS13.
Crossref
Crossref
Shadi Saleh, Amena El Harakeh, Maysa Baroud, Najah Zeineddine, Angie Farah & Abla Mehio Sibai. (2018) Costs associated with management of non-communicable diseases in the Arab Region: a scoping review. Journal of Global Health 8:2.
Crossref
Crossref
Asrul A. Shafie & Chin H. Ng. 2018. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries
129
142
.
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
Amir Farshchi, Rokhsareh Aghili, Maryam Oskuee, Marjan Rashed, Sina Noshad, Abbas Kebriaeezadeh, Maryam Kia & Alireza Esteghamati. (2016) Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study. BMC Endocrine Disorders 16:1.
Crossref
Crossref
Apostolos Tsapas, Thomas Karagiannis & Eleni Bekiari. (2015) Premixed insulin regimens for type 2 diabetes. Endocrine 51:3, pages 387-389.
Crossref
Crossref
Guillermo Dieuzeide, Lee-Ming Chuang, Abdulrahman Almaghamsi, Alexey Zilov, Jian-Wen Chen & Fernando J. Lavalle-González. (2014) Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Primary Care Diabetes 8:2, pages 111-117.
Crossref
Crossref
E V Surkova. (2012) Biphasic insulin analog NovoMix 30 is a possible solution to overcome key problems of biphasic human insulin therapy for DM type 2 patients. Problems of Endocrinology 58:4, pages 58-62.
Crossref
Crossref
Diego Fernández-García & Arantzazu Sebastián-Ochoa. (2012) Insulina aspart en pacientes con diabetes tipo 2. Avances en Diabetología 28, pages 27-31.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
277
292
.
P. Rys, O. Pankiewicz, K. Łach, A. Kwaskowski, I. Skrzekowska-Baran & M.T. Malecki. (2011) Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review. Diabetes & Metabolism 37:3, pages 190-200.
Crossref
Crossref
Walid K. H. Fakhoury, Hartmut Richter & Torsten E. Christensen. (2010) Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes. Advances in Therapy 27:11, pages 859-869.
Crossref
Crossref